Effect of Early Administration of TXA in Adult Hip Fractures

A

Ascension Genesys Hospital

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Postoperative Blood Loss

Treatments

Drug: Tranexamic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT05047133
1722787-1

Details and patient eligibility

About

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

Exclusion criteria

  • Polytrauma patients
  • Previous operation on the ipsilateral hip
  • Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  • Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
  • History of seizure disorder
  • Patients on birth control
  • Pregnant Women
  • Prisoners
  • Active thromboembolic disease (DVT/PE, MI, Stroke)

Trial design

170 participants in 2 patient groups

Early Adminstration of TXA + Intraoperative TXA
Experimental group
Description:
This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
Treatment:
Drug: Tranexamic acid
Intraoperative only TXA
Other group
Description:
This group will only receive the intraoperative TXA.
Treatment:
Drug: Tranexamic acid

Trial contacts and locations

0

Loading...

Central trial contact

Jacob Hinkley, DO, MS; Jacob Lytle, DO

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems